Waldenström macroglobulinemia: A review of therapy

American Journal of Hematology

Volumn 79, Issue 2, 2005, Pages 147-157

  Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hyperviscosity syndrome; Lymphoplasmacytic lymphoma; Monoclonal antibody therapy; Monoclonal gammopathy; Waldenstr m macroglobulinemia

Indexed keywords

ALKYLATING AGENT; ANTIHISTAMINIC AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; CARMUSTINE; CD20 ANTIGEN; CD4 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HEMOGLOBIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; M PROTEIN; MELPHALAN; MITOXANTRONE; MONOCLONAL ANTIBODY; OBLIMERSEN; PENTOSTATIN; PHOSPHODIESTERASE IV INHIBITOR; PLASMA PROTEIN; PREDNISONE; PROTEIN; PROTEIN BCL 2; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG SAFETY; FEVER; GRANULOCYTOPENIA; HEMOLYSIS; HUMAN; HYPERVISCOSITY SYNDROME; HYPOTENSION; IMMUNE DEFICIENCY; INCIDENCE; INFECTION; KIDNEY DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; NEPHELOMETRY; NEUROLOGIC DISEASE; NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; RADIOIMMUNOTHERAPY; REVIEW; RIGOR; SKIN MANIFESTATION; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; PLASMA EXCHANGE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; WALDENSTROM MACROGLOBULINEMIA;

EID: 20044392019     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20363     Document Type: Review

References (108)

1. Waldenström J. To treat or not to treat, this is the real question. Leuk Res 1991;15:407-408.
2. Keren DF, Alexanian R, Goeken JA, Gorevic PD, Kyle RA, Tomar RH. Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies. Arch Pathol Lab Med 1999;123:106-107.
3. Gertz MA, Fonseca R, Rajkumar SV. Waldenström's macroglobulinemia. Oncologist 2000;5:63-67.
4. Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987;62:719-731.
5. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003;30:116-120.
6. Bjorkholm M, Johansson E, Papamichael D, et al. Patterns of clinical presentation, treatment, and outcome in patients with Waldenström's macroglobulinemia: a two-institution study. Semin Oncol 2003;30:226-230.
7. Cesana C, Miqueleiz S, Bernuzzi P, et al. Smouldering Waldenström's macroglobulinemia: factors predicting evolution to symptomatic disease. Semin Oncol 2003;30:231-235.
8. Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Asymptomatic Waldenström's macroglobulinemia. Semin Oncol 2003;30:206-210.
9. Morra E, Cesana C, Klersy C, et al. Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy. Semin Oncol 2003;30:172-177.
10. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993;11:1553-1558.
11. Dalakas MC, Flaum MA, Rick M, Engel WK, Gralnick HR. Treatment of polyneuropathy in Waldenström's macroglobulinemia: role of paraproteinemia and immunologic studies. Neurology 1983;33:1406-1410.
12. Kyle RA, Greipp PR, Gertz MA, et al. Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000;108:737-742.
13. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit [published erratum appears in Ann Hematol 2002;81:124]. Ann Hematol 2001;80:722-727.
14. Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001;115:575-582.
15. Ngan S, Rohatiner AZ, Matthews J, et al. Waldenström's macroglobulinemia: a retrospective analysis of 40 patients from 1972 to 2001. Semin Oncol 2003;30:236-238.
16. Case DC Jr. Combination chemotherapy (M-2) protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for Waldenström macroglobulinemia: preliminary report. Blood 1982;59:934-937.
17. Case DC Jr, Ervin TJ, Boyd MA, Redfield DL. Waldenström's macroglobulinemia: long-term results with the M-2 protocol. Cancer Invest 1991;9:1-7.
18. Petrucci MT, Awisati G, Tribalto M, Giovangrossi P, Mandelli F. Waldenström's macroglobulinaemia: Results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 1989;226:443-447.
19. Cardamone JM, Kimmerle RI, Marshall EY. Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating drugs. Am J Med 1974;57:836-842.
20. Petersen HS. Erythroleukaemia in a melphalan-treated patient with primary macroglobulinaemia. Scand J Haematol 1973;10:5-11.
21. Horsman DE, Card RT, Skinnider LF. Waldenström macroglobulinemia terminating in acute leukemia: A report of three cases. Am J Hematol 1983;15:97-101.
22. Siddiqui A, Melamed MR, Abbi R, Ahmed T. Mucinous (colloid) carcinoma of urinary bladder following long-term cyclophosphamide therapy for Waldenström's macroglobulinemia. Am J Surg Pathol 1996;20:500-504.
23. Rodriguez JN, Fernandez-Jurado A, Martino ML, Prados D. Waldenström's macroglobulinemia complicated with acute myeloid leukemia: report of a case and review of the literature. Haematologica 1998;83:91-92.
24. Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990;75:1928-1931.
25. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenström's macroglobulinemia. Am J Med 1993;95:49-52.
26. Zinzani PL, Gherlinzoni F, Bendandi M, et al. Fludarabine treatment in resistant Waldenström's macroglobulinemia. Eur J Haematol 1995;54:120-123.
27. Leblond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. J Clin Oncol 1998;16:2060-2064.
28. Thalhammer-Scherrer R, Geissler K, Schwarzinger I, et al. Fludarabine therapy in Waldenström's macroglobulinemia. Ann Hematol 2000;79:556-559.
29. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999;17:546-553.
30. Levy V, Porcher R, Leblond V, et al. Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality adjusted survival analysis [abstract]. Blood 2000;96(Pt 1):760a.
31. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001;98:41-48.
32. Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenström's macroglobulinemia: an update of a US intergroup trial (SWOG S9003). Semin Oncol 2003;30:220-225.
33. Fassas A, Dhodapkar M, Barlogie B, et al. Fludarabine for Waldenström's macroglobulinemia: update of Southwest Oncology Intergroup S9003 Trial [abstract]. Blood 2002;100(Pt 1):396a-397a.
34. Lewandowski K, Halaburda K, Hellmann A. Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine. Leuk Lymphoma 2002;43:361-363.
35. Leblond V, Levy V, Maloisel F, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin- prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood 2001;98:2640-2644.
36. Fenchel K, Wijermans P, Mitrou PS, Hoelzer D, Bergmann L. Fludarabine is an effective agent in immunocytic lymphoma. Onkologie 1994;17:508-513.
37. Bjorkholm M, Celsing F, Runarsson G, Waldenström J. Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenström's macroglobulinemia. Int J Hematol 1995;62:117-120.
38. Costa P, Luzzati R, Nicolato A, et al. Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenström's macroglobulinemia treated with fludarabine. Leuk Lymphoma 1998;28:617-620.
39. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993;118:195-198.
40. Delannoy A, Ferrant A, Martiat P, Bosly A, Zenebergh A, Michaux JL. 2-Chlorodeoxyadenosine therapy in Waldenström's macroglobulinaemia. Nouv Rev Fr Hematol 1994;36:317-320.
41. Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br J Haematol 1998;103:690-695.
42. Hellmann A, Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Robak T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur J Haematol 1999;63:35-41.
43. Fridrik MA, Jager G, Baldinger C, Krieger O, Chott A, Bettelheim P. First-line treatment of Waldenström's disease with cladribine. Ann Hematol 1997;74:7-10.
44. Betticher DC, Hsu Schmilz S-F, Ratschiller D, et al. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenslröm's macroglobulinaemia. Br J Haematol 1997;99:358-363.
45. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2-Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. Ann Oncol 1994;5:288-289.
46. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untrealed Waldenström's macroglobulinemia. Semin Oncol 2003;30:243-247.
47. Baltz JK, Montello MJ. Cladribine for the treatment of hematologic malignancies. Clin Pharm 1993;12:805-813.
48. Bryson HM, Sorkin EM. Cladribine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993;46:872-894.
49. Van Den Neste E, Louviaux I, Michaux JL, et al. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′- deoxyadenosine. Br J Haematol 1999;105:268-270.
50. Tetreault SA, Saven A. Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenström macroglobulinemia. Leuk Lymphoma 2000;37:125-130.
51. Van Den Neste E, Delannoy A, Feremans W, Ferrant A, Michaux L. Second primary tumors and immune phenomena after fludarabine or 2-chloro-2′- deoxyadenosine treatment. Leuk Lymphoma 2001;40:541-550.
52. Krishna VM, Carey RW, Bloch KJ. Marked increase in serum IgM during treatment of Waldenström's macroglobulinemia with cladribine. N Engl J Med 2003;348:2045-2046.
53. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999;10:1525-1527.
54. White CA. Rituximab immunotherapy for non-Hodgkin's lymphoma. Cancer Biother Radiopharm 1999;14:241-250.
55. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000;27(Suppl 12):79-85.
56. Treon SP, Agus TB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia. J Immunother 2001;24:272-279.
57. Dimopoulos MA, Kiamouris C, Karkantaris C, Mitsouli C, Viniou N. Prospective evaluation of rituximab for the treatment of Waldenström's macroglobulinemia [abstract]. Blood 2000;96(Pt 1):169a.
58. Treon SP, Mitsiades CS, Mitsiades NS, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B-cell malignancies [abstract]. Blood 2000;96(Pt 1):99a.
59. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma 2002;3:163-166.
60. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-2333.
61. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047-2055.
62. Donnelly GB, Bober-Sorcinelli K, Jacobson R, Portlock CS. Abrupt IgM rise following treatment with rituximab in patients with Waldenström's macroglobulinemia (WM) [abstract]. Blood 2001;98(Pt 2):240b-241b.
63. Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenström's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003;30:121-126.
64. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole D, Gertz MA. The initial "flare" of IgM level after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group (ECOG) study [abstract]. Blood 2003;102(Pt 1):448a-449a.
65. Jourdan E, Topart D, Richard B, Jourdan J, Sotto A. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. Leuk Lymphoma 2003;44:889-890.
66. O'Reilly RA, MacKenzie MR. Primary macrocryogelglobulinemia: remission with adrenal corticosteroid therapy. Arch Intern Med 1967;120:234-248.
67. Jane SM, Salem HH. Treatment of resistant Waldenström's macroglobulinemia with high dose glucocorticosteroids. Aust N Z J Med 1988;18:77-78.
68. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004 Dec;19:3054-3061 (Epub 2004 Oct 19).
69. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004;4:398-402.
70. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003 May 15;101:3827-3834 (Epub 2003 Jan 30).
71. Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenström's macroglobulinemia with thalidomide. J Clin Oncol 2001;19:3596-3601.
72. Coleman M, Leonard JP, Nahum K, Michaeli J. Non-myelosuppressive therapy with BLT-D (Biaxin®, low dose thalidomide and dexamethasone) is highly active in Waldenström's macroglobulinemia and myeloma [abstract]. Blood 2000;96(Pt 1):167a.
73. Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenström's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol 2003;30:270-274.
74. Dimopoulos MA, Tsatalas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003;30:265-269.
75. Branagan AR, Hunter Z, Santos D, Moran J, Treon SP. Thalidomide and rituximab in Waldenström's macroglobulinemia [abstract]. Blood 2004;104:415a.
76. Desikan R, Dhodapkar M, Siegel D, et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia. Br J Haematol 1999;105:993-996.
77. Dreger P, Glass B, Kuse R, et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia. Br J Haematol 1999;106:115-118.
78. Yang L, Wen B, Li H, et al. Autologous peripheral blood stem cell transplantation for Waldenström's macroglobulinemia. Bone Marrow Transplant 1999;24:929-930.
79. Martino R, Shah A, Romero P, et al. Allogeneic bone marrow transplantation for advanced Waldenström's macroglobulinemia. Bone Marrow Transplant 1999;23:747-749.
80. Anagnostopoulos A, Dimopoulos MA, Aleman A, et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenström's macroglobulinemia. Bone Marrow Transplant 2001;27:1027-1029.
81. Tournilhac O, Leblond V, Tabrizi R, et al. Transplantation in Waldenström's macroglobulinemia: The French experience. Semin Oncol 2003;30:291-296.
82. Anagnostopoulos A, Giralt S. Stem cell transplantation (SCT) for Waldenström's macroglobulinemia (WM). Bone Marrow Transplant 2002;29:943-947.
83. Al-Katib AM, Mensah-Osman E, Aboukameel A, Mohammad R. The Wayne State University Waldenström's Macroglobulinemia preclinical model for Waldenström's macroglobulinemia. Semin Oncol 2003;30:313-317.
84. Ueda T, Hatanaka K, Kosugi S, Kishino BI, Tamaki T. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinemia with severe pancytopenia. Bone Marrow Transplant 2001;28:609-611.
85. Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC, Alberto P. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 1999;79:1215-1219.
86. Van Den Neste E, Louviaux I, Michaux JL, et al. Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia 2000;14:1136-1142.
87. Weber DM, Delasalle K, Gavino M, Wood A, Cabanillas F, Alexanian R. Primary treatment of Waldenström's macroglobulinemia (WM) with subcutaneous 2-chlorodeoxyadenosine (2-CdA) and oral cyclophosphamide [abstract]. Blood 1997;90(Suppl 1 Pt 1):357a.
88. Weber DM, Wang M, Delasalle KB, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine (2CdA) and cyclophosphamide (Cy) alone or in combination with rituximab (Rit) for previously untreated Waldenström's macroglobulinemia (WM) [abstract]. Blood 2004;104:413a.
89. Dimopoulos MA, Hamilos G, Efstathiou E, et al. Treatment of Waldenström's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 2003;44:993-996.
90. Treon SP, Wasi P, Emmanouilides CA, et al. Combination therapy with rituximab and fludarabine is highly active in Waldenström's macroglobulinemia [abstract]. Blood 2002;100(Pt 1):211a.
91. Petrucci MT, Annibali O, Levi A, et al. Oral melphalan, cyclophosfamide and prednisone (MCP) in 72 newly diagnosed Waldenström's macroglobulinemia patients: results and costs analysis [abstract]. Blood 2004;104:901a.
92. Treon SP, Branagan A, Wasi P, et al. Combination therapy with rituximab and fludarabine in Waldenström's macroglobulinemia [abstract]. Blood 2004;104:215a.
93. Dimopoulos MA, Kyrtsonis MC, Tsatalas C, et al. Primary treatment of Waldenström's macroglobulinemia (WM) with dexamethasone, rituximab and cyclophosphamide [abstract]. Blood 2004;104:215a.
94. Hunter Z, Branagan A, Treon S. CHOP plus rituximab (CHOP-R) in Waldenström's macroglobulinemia (WM) [abstract]. Blood 2004;104:314b.
95. Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD. Pentostatin, cyclophosphamide and rituximab: an effective regimen for patients with Waldenström's macroglobulinemia [abstract]. Proc Third International Workshop on Waldenström's Macroglobulinemia; 2004 October 7-10; Paris, France, p 58.
96. Treon SP, Branagan A, Wasi P, et al. Combination therapy with rituximab and fludarabine in Waldenström's macroglobulinemia [abstract]. Program and abstract book of the Third International Workshop on Waldenström's Macroglobulinemia; 2004 October 7-10; Paris, France, p 57.
97. Thomas EL, Oik RJ, Markman M, Braine H, Patz A. Irreversible visual loss in Waldenström's macroglobulinaemia. Br J Ophthalmol 1983;67:102-106.
98. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999;131:453-462.
99. Buskard NA, Gallon DA, Goldman JM, et al. Plasma exchange in the long-term management of Waldenström's macroglobulinemia. Can Med Assoc J 1977;117:135-137.
100. Avnstorp C, Nielsen H, Drachmann O, Hippe E. Plasmapheresis in hyperviscosity syndrome. Acta Med Scand 1985;217:133-137.
101. Emmanouilides C. Radioimmunotherapy for Waldenström's macroglobulinemia. Semin Oncol 2003;30:258-261.
102. Emmanouilides C, Silverman D, Leigh B, Territo M. Successful treatment of Waldenström's macroglobulinemia with Zevalin-based therapy: a case report [abstract]. Blood 2001;98(Pt 2):241b.
103. Gocke C, Frankel SR. Bcl-2 expression in Waldenström macroglobulinemia [abstract]. Blood 2001;98(Pt 1):149a.
104. Nichols GL, Stein CA. Modulation of the activity of Bcl-2 in Waldenström's macroglobulinemia using antisense oligonucleotides. Semin Oncol 2003;30:297-299.
105. Frankel SR. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenström's macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol 2003;30:300-304.
106. Zeldis JB, Schafer PH, Bennett BL, Mercurio F, Stirling DI. Potential new therapeutics for Waldenström's macroglobulinemia. Semin Oncol 2003;30:275-281.
107. Chen CI, White D, Kouroukis CT, et al. Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenström's macroglobulinemia (WM) [abstract]. Blood 2004;104:896a.
108. Gertz MA. Waldenström's macroglobulinemia: a review of therapy. Leuk Lymphoma 2002;43:1517-1526.